Overview

Extension Trial Assessing the Safety and Efficacy of BI 655066/ABBV-066/Risankizumab in Patients With Moderate to Severe Chronic Plaque Psoriasis

Status:
Completed

Trial end date:
2018-09-04

Target enrollment:

Participant gender:

Summary

The primary objective of Study M16-009 was to investigate the safety of risankizumab in participants with moderate to severe chronic plaque psoriasis who were receiving long-term treatment. Additional study objectives were to further investigate the long-term efficacy, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of risankizumab.

Phase:

Phase 2

Details

Lead Sponsor:

AbbVie

Collaborator:

Boehringer Ingelheim